4D Molecular Therapeutics
FDMT • NASDAQ
4D Molecular Therapeutics is a biotechnology company in the healthcare sector trading on NASDAQ, led by CEO David H. Kirn, with a market cap of $476.3M.
CEODavid H. Kirn
Next Earnings
Upcoming earnings announcement for 4D Molecular Therapeutics
Date
Thursday, May 7, 2026 (in a month)
Timing
After Market Close (4:00 PM New York)
Fiscal Period
Q1 2026
EPS Estimate
-$0.99
Revenue Estimate
$3.1M
Earnings History
Past 12 earnings reports for 4D Molecular Therapeutics
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Mar 18, 2026 | Q4 2025 | $0.43Est: -$0.53 | +181.1% | $85.1MEst: $32.2M | +163.9% | — |
| Nov 10, 2025 | Q3 2025 | -$1.01Est: -$1.00 | -1.0% | $90.0KEst: $645.8K | -86.1% |  10-Q |
| Aug 11, 2025 | Q2 2025 | -$0.98Est: -$0.77 | -27.3% | $15.0KEst: $737.7K | -98.0% | 10-Q |
| May 8, 2025 | Q1 2025 | -$0.86Est: -$0.86 | 0.0% | $14.0KEst: $529.7K | -97.4% | 10-Q |
| Feb 28, 2025 | Q4 2024 | -$0.90Est: -$0.83 | -8.4% | $1.0KEst: $2.2M | -100.0% | 10-K |
| Nov 13, 2024 | Q3 2024 | -$0.79Est: -$0.70 | -12.9% | $3.0KEst: $560.0K | -99.5% | 10-Q |
| Aug 8, 2024 | Q2 2024 | -$0.63Est: -$0.71 | +11.3% | $5.0K | — | 10-Q |
| May 9, 2024 | Q1 2024 | -$0.66Est: -$0.74 | +10.8% | $28.0KEst: $780.0K | -96.4% | 10-Q |
| Feb 29, 2024 | Q4 2023 | -$0.77Est: -$0.74 | -4.1% | -$17.0KEst: $2.1M | -100.8% | 10-K |
| Nov 9, 2023 | Q3 2023 | -$0.24Est: -$0.54 | +55.6% | $20.2MEst: $9.9M | +104.7% | — |
| Aug 9, 2023 | Q2 2023 | -$0.77Est: -$0.81 | +4.9% | $239.0KEst: $850.0K | -71.9% | 10-Q |
| May 10, 2023 | Q1 2023 | -$0.88Est: -$0.90 | +2.2% | $298.0KEst: $1.0M | -71.1% | 10-Q |